TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

David R. Epstein, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 370 shares of the company's Class A Common Stock. The shares were sold on February 3, 2025, at an average price of $53.31 ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 51,813 call options on the company. This is an increase of approximately ...

Tempus AI , Inc. (NASDAQ: TEM )董事David R. Epstein近期出售了370股该公司A类普通股。这些股票于2025年2月3日以平均每股$53.31的价格售出，总价值约$19,724。此后，TEM股价已上涨至$69.18，这家市值$97.4亿的公司年初至今已实现105%的显著涨幅。 InvestingPro ...